

Drugs Under Patent

A comprehensive guide to FDA-approved pharmaceuticals under patent and marketing exclusivity

1989 Edition



Drugs Under Patent

1989 Edition

Published by: FOI Services, Inc. 12315 Wilkins Avenue Rockville MD 20852-1877, U.S.A.

> Phone: 301/881-0410 Fax: 301/881-0415

International Standard Book Number: 0-9622958-0-9

Printed in the United States of America

Copyright © 1989 by FOI Services, Inc.

All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the publisher's written permission in each instance.

All information included in **Drugs Under Patent** was derived directly from FDA's computer tape of approved drug products. Therefore, the publisher of this book cannot accept responsibility for errors or omissions in the listings. This book should be regarded only as a guide to patent and exclusivity expirations; further verification of these data should be done before accepting this information as correct.



Drugs Under Patent

1989 Edition

Published by: FOI Services, Inc. 12315 Wilkins Avenue Rockville MD 20852-1877, U.S.A.

> Phone: 301/881-0410 Fax: 301/881-0415

International Standard Book Number: 0-9622958-0-9

Printed in the United States of America

Copyright © 1989 by FOI Services, Inc.

All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the publisher's written permission in each instance.

All information included in **Drugs Under Patent** was derived directly from FDA's computer tape of approved drug products. Therefore, the publisher of this book cannot accept responsibility for errors or omissions in the listings. This book should be regarded only as a guide to patent and exclusivity expirations; further verification of these data should be done before accepting this information as correct.

Introduction

On September 24, 1984, the Drug Price Competition and Patent Term Restoration Act was signed into law. Among other things, the Act determined which drugs qualify for periods of exclusivity (during which Abbreviated New Drug Applications for those drugs may either not be submitted or made effective), and provided a mechanism for extending the patent term of a drug which encountered delays during the review process.

Drugs Under Patent provides complete listings of pharmaceuticals affected by the 1984 Act, offering index points by company name, drug trade and generic names, expiration date, dosage form, exclusivity code, patent number and NDA number.

All data used to prepare **Drugs Under Patent** were obtained from the Food & Drug Administration's listing of approved drug products as of June 1989. Therefore, the publisher of this book cannot accept responsibility for errors or omissions in the listings. This book should be regarded only as a guide to patent and exclusivity expirations; further verification of these data should be done before accepting this information as correct.

Important Notice

This printing of **Drugs Under Patent - 1989 Edition** is a replacement for an earlier press run, which contained incorrect data.

If you have any copies of this book with a <u>blue cover</u>, please discard them, as they contain several incorrect patent and exclusivity dates.

Drugs Under Patent

Company Index	
This main index is the only index containing all of the fields:	1
Company Name • Generic Name • Trade Name • Dosage Form • Patent Date •	
Exclusivity Date • Exclusivity Code • NDA Number • Approval Date • Patent Number •	Co.
Withdrawn Date • Discontinued Date	
Trade Name Index	2
	4
Trade Name • Generic Name • Company Name	Trade
ap 200 mg ag by sambone regional as years want a series and a series a	
Generic Name Index	2
	3
Generic Name • Company Name • Expiration Date & Code	Gen.
Date Index	1
	4
Expiration Date & Code • Generic Name • Company Name	Date
Dosage Form Index	-
Doduge Form mack	9
Dosage Form • Generic Name • Company Name • Expiration Date & Code	Forn
13/3·200	
Exclusivity Code Index	0
Exclusivity Code maex	6
Exclusivity Code • Generic Name • Company Name • Expiration Date & Code	Code
Explication of the Paris Company Name Explication Date a code	
Patent Number Index	7
r dient number maex	1
Patent Number • Generic Name • Company Name	Pate
t-Dischargement	No.
	0
NDA Number Index	O
19 w 20 km 8 km 182	ND
NDA Number • Generic Name • Company Name	No

此为试读,需要完整PDF请访问: www.ertongbook.com

Section 1 — Company Index

Section 1 lists drugs under patent alphabetically by company name. This is the main index in this book, and the only index containing all of the information for each product. Within each company, individual drugs are listed alphabetically by generic name. The company name has been standardized for each reference; if the company or product you are seeking does not appear, be sure to check the listing for the parent company. Company names that denote names of people are alphabetized by surname (e.g., Eli Lilly will be found under "L").

Please note that blank fields indicate that the data are not applicable or do not appear on FDA's master list of approved drug products.

Sample Record:

Ciba Pharmaceutical 1

Chlorthalidone 25Mg; Metoprolol Tartrate 100Mg (2) Lopressidone (3)

Capsule; Oral (4)

NDA No: N19451(5) Approved: 12/31/87 (6)

7 Patent Date: 12/21/93

8 Exclusivity Date: 12/31/90 9 Exclusivity Code: NC

10 Patent Number: 3998790

11) Discontinued: (12) Withdrawn:

Key:

- 1 Company Name
- 2 Drug generic name and strength
- 3 Drug trade name if no trade name, then generic name repeated
- 4 Dosage form and route
- 5 NDA (FDA New Drug Application) number
- 6 Date of NDA approval
- 7 Date of patent expiration
- 8 Date of exclusivity expiration
- 9 Exclusivity code see section 6 for a translation of these codes
- 10 Patent number
- 11 Date the manufacturer discontinued product marketing (if applicable)
- 12 Date of withdrawal of FDA approval (if applicable)

Abbott Laboratories

Calcitriol 0.001Mg/MI Patent Date: 12/29/98

Calcijex **Exclusivity Date:**

Injection; Intravenous **Exclusivity Code:** NDA No: 18874 Approved: 09/25/86 Patent Number: 4308264

Calcitriol 0.001Mg/MI Patent Date: 10/10/89

Calcijex **Exclusivity Date:** 09/24/89

Injection; Intravenous Exclusivity Code: NDF NDA No: 18874 Patent Number: 3697559 Approved: 09/25/86

Calcitriol 0.002Mg/MI Patent Date: 12/29/98

Exclusivity Date: Calcijex Injection; Intravenous **Exclusivity Code:**

NDA No: 18874 Patent Number: Approved: 09/25/86 4308264

Calcitriol 0.002Mg/MI Patent Date: 10/10/89

Exclusivity Date: 09/24/89 Calcijex

Injection; Intravenous Exclusivity Code: NDF NDA No: 18874 Patent Number: Approved: 09/25/86 3697559

Carteolol Hydrochloride 10Mg Patent Date: 10/07/92 Cartrol Exclusivity Date: 12/28/93

Tablet: Oral Exclusivity Code: NCE NDA No: 19204 Approved: 12/28/88 Patent Number: 3910924

Carteolol Hydrochloride 2.5Mg Patent Date: 10/07/92

Cartrol Exclusivity Date: 12/28/93 Tablet: Oral Exclusivity Code: NCE

Patent Number: NDA No: 19204 Approved: 12/28/88 3910924

Carteolol Hydrochloride 5Mg Patent Date: 10/07/92

Exclusivity Date: Cartrol 12/28/93 Tablet; Oral Exclusivity Code: NCE

Patent Number: NDA No: 19204 Approved: 12/28/88 3910924

Patent Date: Etomidate 2Mg/MI

Amidate Exclusivity Date: 09/07/92 Exclusivity Code: NCE Injection; Intravenous

NDA No: 18227 Patent Number: Approved: 09/07/82

Leuprolide Acetate 7.5Mg/Vial Patent Date:

Lupron Depot Exclusivity Date: 01/26/92

Approved: 01/26/89

Injection; Intramuscular Exclusivity Code: NP NDA No: 19732 Patent Number:

Patent Date:	01/25/96
Exclusivity Date:	04/09/90
Exclusivity Code:	NCE
Patent Number:	4005063
Patent Data:	07/17/00

Protirelin 0.5Ma/MI

Leuprolide Acetate 7.5Mg/Vial

Lupron Depot Injection: Intramuscular NDA No: 19732

Patent Date: 07/17/90 Thypinone **Exclusivity Date:** Injection; Intravenous **Exclusivity Code:** NDA No: 17638 Approved: 11/05/76 Patent Number: 3746697

Approved: 01/26/89

Terazosin Hydrochloride 10Mg Patent Date: 02/17/00 Exclusivity Date: Hytrin 08/07/92 Tablet: Oral Exclusivity Code: NCE NDA No: 19057 Approved: 08/07/87 Patent Number: 4251532

Terazosin Hydrochloride 10Mg Patent Date: 05/31/94 Hytrin **Exclusivity Date:** Tablet: Oral **Exclusivity Code:**

NDA No: 19057 Patent Number: Approved: 08/07/87 4026894 Terazosin Hydrochloride 10Mg Patent Date: 09/05/95 Hytrin **Exclusivity Date:**

Tablet; Oral Exclusivity Code: NDA No: 19057 Approved: 08/07/87 Patent Number: 4112097

Terazosin Hydrochloride 1Mg Patent Date: 09/05/95 Hytrin **Exclusivity Date:**

Tablet: Oral Exclusivity Code: NDA No: 19057 Approved: 08/07/87 Patent Number: 4112097

Terazosin Hydrochloride 1Mg Patent Date: 02/17/00

Hytrin Exclusivity Date: 08/07/92 Tablet: Oral Exclusivity Code: NCF Patent Number: NDA No: 19057 Approved: 08/07/87 4251532

Terazosin Hydrochloride 1Mg Patent Date: 05/31/94 Hytrin **Exclusivity Date:**

Exclusivity Code: Tablet: Oral NDA No: 19057 Approved: 08/07/87 Patent Number: 4026894

Terazosin Hydrochloride 2Mg Patent Date: 05/31/94 Hytrin **Exclusivity Date:**

Tablet: Oral **Exclusivity Code:** NDA No: 19057 Approved: 08/07/87 Patent Number: 4026894

Terazosin Hydrochloride 2Mg		Patent Date:	09/05/95
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 08/07/87	Patent Number:	4112097
1107110.10007	Apploved. Colomor	r dicint redilloct.	4112031
Terazosin Hydrochloride 2Mg		Patent Date:	02/17/00
Hytrin		Exclusivity Date:	08/07/92
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 19057	Approved: 08/07/87	Patent Number:	4251532
NDA NO. 19037	Approved. 00/07/07	ralent Number.	4231332
Terazosin Hydrochloride 5Mg		Patent Date:	05/31/94
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
	A		400000
NDA No: 19057	Approved: 08/07/87	Patent Number:	4026894
Terazosin Hydrochloride 5Mg		Patent Date:	09/05/95
Hytrin		Exclusivity Date:	nill.
Tablet; Oral		Exclusivity Code:	
	4		444000
NDA No: 19057	Approved: 08/07/87	Patent Number:	4112097
Terazosin Hydrochloride 5Mg		Patent Date:	02/17/00
Hytrin		Exclusivity Date:	08/07/92
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 00/07/07	Patent Number:	
NDA NO. 19057	Approved: 08/07/87	Palent Number.	4251532
Adria Laboratories			
Bentiromide 500Mg/7.5MI		Patent Date:	07/10/90
Chymex		Exclusivity Date:	
Solution; Oral		Exclusivity Code:	
	A		074504
NDA No: 18366	Approved: 12/29/83	Patent Number:	3745212
Bentiromide 500Mg/7.5MI		Patent Date:	04/02/9
Chymex		Exclusivity Date:	12/29/9
Solution; Oral		Exclusivity Code:	
	Approved: 12/00/02		380156
NDA No: 18366	Approved: 12/29/83	Patent Number:	380156
Alcon Laboratories			
Apraclonidine Hydrochloride E	q 1% Base	Patent Date:	05/14/0
lopidine	Samuel Alexand	Exclusivity Date:	12/31/9
Solution; Ophthalmic		Exclusivity Code:	
NDA No: 19779	Approved: 12/31/87	Patent Number:	451719
Jeros Santago	terries second	Eurosideacto	
Betaxolol Hydrochloride Eq 0.	5% Base	Patent Date:	01/19/9
Betoptic		Exclusivity Date:	
Solution; Ophthalmic		Exclusivity Code:	
NDA No: 19270	Approved: 08/30/85	Patent Number:	431170
110/11/0. 102/0	, pp10100. 00/00/00	r atom radinosi.	401110

Co

Betaxolol Hydrochloride Eq 0.5 Betoptic	% Base	Patent Date: Exclusivity Date:	08/03/99
Solution; Ophthalmic		Exclusivity Code:	1
NDA No: 19270	Approved: 08/30/85	Patent Number:	4342783
Betaxolol Hydrochloride Eq 0.5	5% Base	Patent Date:	07/31/99
Betoptic		Exclusivity Date:	08/30/90
Solution; Ophthalmic		Exclusivity Code:	
NDA No: 19270	Approved: 08/30/85	Patent Number:	4252984
Fluorometholone Acetate 0.1%	Approved: 1200/62	Patent Date:	
Flarex		Exclusivity Date:	02/11/89
Suspension; Ophthalmic		Exclusivity Code:	NE
NDA No: 19079	Approved: 02/11/86	Patent Number:	
Suprofen 1%		Patent Date:	07/12/96
Profenal		Exclusivity Date:	12/23/91
Solution; Ophthalmic		Exclusivity Code:	NDF
NDA No: 19387	Approved: 12/23/88	Patent Number:	4035376
Suprofen 1%		Patent Date:	12/17/02
Profenal		Exclusivity Date:	12/24/90
Solution; Ophthalmic		Exclusivity Code:	NCE
NDA No: 19387	Approved: 12/23/88	Patent Number:	4559343
Allergan Pharmaceu	ticals		
Dipivefrin Hydrochloride 0.1%		Patent Date:	05/07/91
Propine		Exclusivity Date:	
Solution; Ophthalmic		Exclusivity Code:	
NDA No: 18239	Approved: 05/02/80	Patent Number:	3809714
Dipivefrin Hydrochloride 0.1%		Patent Date:	10/01/91
Propine		Exclusivity Date:	
Solution; Ophthalmic		Exclusivity Code:	
NDA No: 18239	Approved: 05/02/80	Patent Number:	3839584
Flurbiprofen Sodium 0.03%		Patent Date:	08/28/90
Ocufen		Exclusivity Date:	12/31/91
Solution; Ophthalmic		Exclusivity Code:	NCE
NDA No: 19404	Approved: 12/31/86	Patent Number:	3755427
Flurbiprofen Sodium 0.03%		Patent Date:	02/19/93
Ocufen		Exclusivity Date:	
Solution; Ophthalmic		Exclusivity Code:	

Co.

Diabeta	
Tablet; Oral	
NDA No: 17532	Approved: 05/01/84
Glyburide 1.25Ma	

Approved: 05/01/84

Glyburide	1.25Mg
Diabeta	
Tablet; Or	al
NDA No	0: 17532

	Patent Date:	04/21/92
	Exclusivity Date:	05/01/94
	Exclusivity Code:	NCE
Approved: 05/01/84	Patent Number:	3426067
	Patent Date:	04/21/92
	Exclusivity Date:	
	Exclusivity Code:	
Approved: 05/01/84	Patent Number:	3454635
	Patent Date:	04/21/92
	Exclusivity Date:	
	Exclusivity Code:	
Approved: 05/01/84	Patent Number:	3507954
	Patent Date:	09/07/93
	Exclusivity Date:	
	Exclusivity Code:	

Patent Number:

4060634

Co.

Patent Date: Glyburide 5Mg 04/21/92 **Exclusivity Date:** Diabeta Tablet: Oral **Exclusivity Code:** NDA No: 17532 Approved: 05/01/84 Patent Number: 3507961 Glyburide 5Mg Patent Date: 04/21/92

Diabeta

Tablet: Oral

NDA No: 17532

Approved: 05/01/84 Glyburide 5Mg Patent Date: 04/21/92 Diabeta **Exclusivity Date:** Tablet: Oral Exclusivity Code: Patent Number: NDA No: 17532 Approved: 05/01/84 3454635

Exclusivity Date:

Exclusivity Code:

Patent Number:

05/01/94

3426067

3507954

NCE

Glyburide 5Mg Patent Date: 04/21/92 Diabeta **Exclusivity Date:**

Tablet: Oral Exclusivity Code: NDA No: 17532 Approved: 05/01/84 Patent Number:

American Hoechst	8	Drugs Under	Patent
Glyburide 5Mg		Patent Date:	09/07/93
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	4060634
Nomifensine Maleate 25Mg		Patent Date:	
Merital		Exclusivity Date:	12/31/89
Capsule; Oral		Exclusivity Code:	NCE
NDA No: 18224	Approved: 12/31/84	Patent Number:	
Nomifensine Maleate 50Mg		Patent Date:	
Merital		Exclusivity Date:	12/31/89
Capsule; Oral		Exclusivity Code:	NCE
NDA No: 18224	Approved: 12/31/84	Patent Number:	
Pentoxifylline 400Mg		Patent Date:	02/02/97
Trental		Exclusivity Date:	
Tablet, Sustained Action; Oral		Exclusivity Code:	
NDA No: 18631	Approved: 08/30/84	Patent Number:	4189469
Pentoxifylline 400Mg		Patent Date:	06/05/90
Trental		Exclusivity Date:	08/30/94
Tablet, Sustained Action; Oral		Exclusivity Code:	NCE
NDA No: 18631	Approved: 08/30/84	Patent Number:	3737433
Protirelin 0.5Mg/MI		Patent Date:	07/17/90
Relefact Trh		Exclusivity Date:	
Injection; Intravenous		Exclusivity Code:	
NDA No: 18087	Approved: 07/18/78	Patent Number:	3746697
Amersham			
Indium In-111 Oxyquinoline 1M	lci/MI	Patent Date:	06/15/99
Indium In-111 Oxyquinoline		Exclusivity Date:	12/23/90
Injectable; Intravenous		Exclusivity Code:	NCE
NDA No: 19044	Approved: 12/23/85	Patent Number:	4335095
Anaquest			
Isoflurane 99.9%		Patent Date:	01/24/93
Forane		Exclusivity Date:	
Liquid; Inhalation		Exclusivity Code:	
NDA No: 17624	Approved: 12/18/79	Patent Number:	3535425
Isoflurane 99.9%		Patent Date:	01/24/93
Forane		Exclusivity Date:	
Liquid; Inhalation		Exclusivity Code:	
NDA No: 17624	Approved: 12/18/79	Patent Number:	3535388

Astra Pharmaceutical

Epinephrine 0.005Mg/MI; Etidocaine Hydrochloride 0.5%

Duranest

Injection; Peridural

NDA No: 17751

Approved: 08/30/76

Approved: 08/30/76

Patent Date:

05/21/91

Exclusivity Date: Exclusivity Code:

Patent Number: 3812147

Epinephrine 0.005Mg/MI; Etidocaine Hydrochloride 0.5%

Duranest

Injection; An, Infiltration

NDA No: 17751

A STATE OF THE PARTY OF THE PAR

Patent Date: Exclusivity Date:

Exclusivity Date:

Patent Number: 3812147

05/21/91

01/21/92

Epinephrine 0.005Mg/MI; Etidocaine Hydrochloride 0.5%

Duranest

Injection; An,Infiltration

NDA No: 17751

Approved: 08/30/76

Patent Date: Exclusivity Date:

Exclusivity Code:

Patent Number: 3862321

Epinephrine 0.005Mg/MI; Etidocaine Hydrochloride 0.5%

Duranest

Injection; Peridural

NDA No: 17751

Approved: 08/30/76

Approved: 08/30/76

Approved: 08/30/76

Patent Date: Exclusivity Date: 01/21/92

Exclusivity Code:

Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/MI;

Etidocaine Hydrochloride 1%

Duranest

Injection; An,Infiltration

NDA No: 17751

Patent Date:

05/21/91

Exclusivity Date: Exclusivity Code:

Patent Number: 3812147

Epinephrine Bitartrate 0.005Mg/Ml; Etidocaine Hydrochloride 1.5%

Etidocaine Hydrochio

Duranest

Injection; Nerve Block

NDA No: 17751

Patent Date:

01/21/92

Exclusivity Date:

Exclusivity Code:

Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/Ml;

Etidocaine Hydrochloride 1%

Duranest

Injection; An,Infiltration

NDA No: 17751

Approved: 08/30/76

01/21/92

Exclusivity Date:

Patent Date:

Exclusivity Code:

Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/MI;

Etidocaine Hydrochloride 1%

Duranest

Injection; Epidural

NDA No: 17751

Approved: 08/30/76

Patent Date:

05/21/91

Exclusivity Date: Exclusivity Code:

Patent Number: 3812147

Epinephrine Bitartrate 0.005Mg/MI; Etidocaine Hydrochloride 1% Patent Date: 01/21/92 Duranest **Exclusivity Date:** Injection; Epidural **Exclusivity Code:** NDA No: 17751 Approved: 08/30/76 Patent Number: 3862321 Epinephrine Bitartrate 0.005Mg/MI; Etidocaine Hydrochloride 1.5% Patent Date: 05/21/91 Duranest **Exclusivity Date:** Injection; Nerve Block **Exclusivity Code:** NDA No: 17751 Approved: 08/30/76 Patent Number: 3812147 Epinephrine Bitartrate 0.005Mg/MI; Etidocaine Hydrochloride 1.5% Patent Date: 05/21/91 Duranest **Exclusivity Date:** Injection; Epidural **Exclusivity Code:** NDA No: 17751 Approved: 08/30/76 Patent Number: 3812147 Epinephrine Bitartrate 0.005Mg/MI; 01/21/92 Etidocaine Hydrochloride 1.5% Patent Date: Duranest **Exclusivity Date:** Injection; Epidural **Exclusivity Code:** NDA No: 17751 Patent Number: Approved: 08/30/76 3862321 Etidocaine Hydrochloride 0.5% Patent Date: 01/21/92 Duranest **Exclusivity Date:** Injection; An, Infiltration **Exclusivity Code:** NDA No: 17751 Approved: 08/30/76 Patent Number: 3862321 Etidocaine Hydrochloride 0.5% Patent Date: 01/21/92 Duranest **Exclusivity Date:** Injection; Peridural **Exclusivity Code:** NDA No: 17751 Approved: 08/30/76 Patent Number: 3862321 Etidocaine Hydrochloride 0.5% Patent Date: 05/21/91 Duranest **Exclusivity Date:** Injection; Peridural **Exclusivity Code:** NDA No: 17751 Approved: 08/30/76 Patent Number: 3812147 Etidocaine Hydrochloride 0.5% Patent Date: 05/21/91 Duranest **Exclusivity Date:** Injection; An, Infiltration **Exclusivity Code:** NDA No: 17751 Patent Number: Approved: 08/30/76 3812147 Etidocaine Hydrochloride 1% Patent Date: 05/21/91 Duranest **Exclusivity Date:** Injection; Epidural **Exclusivity Code:** NDA No: 17751 Patent Number: Approved: 08/30/76 3812147

NDA No: 18891

Co

Etidocaine Hydrochloride 1% Duranest		Patent Date: Exclusivity Date:	01/21/92
Injection; An,Infiltration		Exclusivity Code:	
NDA No: 17751	Approved: 08/30/76	Patent Number:	3862321
Etidocaine Hydrochloride 1%		Patent Date:	01/21/92
Duranest		Exclusivity Date:	
Injection; Epidural		Exclusivity Code:	
NDA No: 17751	Approved: 08/30/76	Patent Number:	3862321
Etidocaine Hydrochloride 1%		Patent Date:	05/21/91
Duranest		Exclusivity Date:	
Injection; An,Infiltration		Exclusivity Code:	
NDA No: 17751	Approved: 08/30/76	Patent Number:	3812147
Mesna 100Mg/MI		Patent Date:	09/02/97
Mesnex		Exclusivity Date:	12/30/95
Injection; Intravenous		Exclusivity Code:	ODE
NDA No: 19884	Approved: 12/30/88	Patent Number:	4220660
Mesna 100Mg/MI		Patent Date:	
Mesnex		Exclusivity Date:	12/30/93
Injection; Intravenous		Exclusivity Code:	NCE
NDA No: 19884	Approved: 12/30/88	Patent Number:	
Berlex Laboratories			
Gadopentetate Dimeglumine 4	69.01Mg/MI	Patent Date:	03/03/04
Magnevist		Exclusivity Date:	06/02/93
Injection; Intravenous		Exclusivity Code:	NCE
NDA No: 19596	Approved: 06/02/88	Patent Number:	4647447
Boehringer Ingelheim	n gioqui		
Chlorthalidone 15Mg		Patent Date:	
Thalitone		Exclusivity Date:	12/20/91
Tablet; Oral		Exclusivity Code:	NS
NDA No: 19574	Approved: 12/20/88	Patent Number:	
Clonidine 0.1Mg/24Hr		Patent Date:	06/28/94
Catapres-Tts-1		Exclusivity Date:	
Film, Controlled Release; Perc		Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4060084
Clonidine 0.1Mg/24Hr		Patent Date:	07/29/92
Catapres-Tts-1		Exclusivity Date:	
Film, Controlled Release; Perc	utaneous	Exclusivity Code:	

Approved: 10/10/84

Patent Number:

3996934

Clonidine 0.1Mg/24Hr		Patent Date:	05/06/97
Catapres-Tts-1		Exclusivity Date:	
Film, Controlled Release; Percut		Exclusivity Code:	STREET, STREET
NDA No: 18891	Approved: 10/10/84	Patent Number:	4201211
Clonidine 0.1Mg/24Hr		Patent Date:	12/17/02
Catapres-Tts-1		Exclusivity Date:	
Film, Controlled Release; Percut	aneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4559222
Clonidine 0.2Mg/24Hr		Patent Date:	06/28/94
Catapres-Tts-2		Exclusivity Date:	
Film, Controlled Release; Percut	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4060084
Clonidine 0.2Mg/24Hr		Patent Date:	05/06/97
Catapres-Tts-2		Exclusivity Date:	
Film, Controlled Release; Percui	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4201211
Clonidine 0.2Mg/24Hr		Patent Date:	12/17/02
Catapres-Tts-2		Exclusivity Date:	
Film, Controlled Release; Percu	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4559222
Clonidine 0.2Mg/24Hr		Patent Date:	07/29/92
Catapres-Tts-2		Exclusivity Date:	
Film, Controlled Release; Percu	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	3996934
Clonidine 0.3Mg/24Hr		Patent Date:	07/29/92
Catapres-Tts-3		Exclusivity Date:	
Film, Controlled Release; Percu	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	3996934
Clonidine 0.3Mg/24Hr		Patent Date:	05/06/97
Catapres-Tts-3		Exclusivity Date:	
Film, Controlled Release; Percu	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4201211
Clonidine 0.3Mg/24Hr		Patent Date:	12/17/02
Catapres-Tts-3		Exclusivity Date:	
Film, Controlled Release; Percu	taneous	Exclusivity Code:	
NDA No: 18891	Approved: 10/10/84	Patent Number:	4559222